Pharmacotherapy for Obesity
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Obesity is an important risk factor for metabolic disease and various cancers. Treatments of obesity include lifestyle intervention,pharmacotherapy, and bariatric surgery. If weight loss with lifestyle intervention is only modest, pharmacotherapy mightbe needed. Pharmacotherapy agents can be grouped by treatment period as short term or long term use agent. Severalsympathomimetic drugs such as benzphetamine, diethylpropion, phendimetrazine and phentermine, are approved for short termtreatment due to their safety issues. For long term treatment, orlistat, lorcaserin, and combination of phentermine/topiramateare approved by U.S. Food and Drug Administration (FDA). Orlistat partially blocks intestinal digestion of fat, therefore producingweight loss. Lorcaserin is a serotonin 2C receptor agonist. The combination of phentermine/topiramate produces a mean weightloss of 8-10 kg. Side effects of each drug are quite different. For obesity patient, side effects are important factor when choosingdrugs. The goal of this article is to review currently available anti-obesity drugs. (J Menopausal Med 2014;20:90-96)
Abstract
Obesity is an important risk factor for metabolic disease and various cancers. Treatments of obesity include lifestyle intervention,pharmacotherapy, and bariatric surgery. If weight loss with lifestyle intervention is only modest, pharmacotherapy mightbe needed. Pharmacotherapy agents can be grouped by treatment period as short term or long term use agent. Severalsympathomimetic drugs such as benzphetamine, diethylpropion, phendimetrazine and phentermine, are approved for short termtreatment due to their safety issues. For long term treatment, orlistat, lorcaserin, and combination of phentermine/topiramateare approved by U.S. Food and Drug Administration (FDA). Orlistat partially blocks intestinal digestion of fat, therefore producingweight loss. Lorcaserin is a serotonin 2C receptor agonist. The combination of phentermine/topiramate produces a mean weightloss of 8-10 kg. Side effects of each drug are quite different. For obesity patient, side effects are important factor when choosingdrugs. The goal of this article is to review currently available anti-obesity drugs. (J Menopausal Med 2014;20:90-96)
참고문헌 (24)
- Flegal KM, "Causespecific excess deaths associated with underweight, overweight, and obesity", JAMA, 298, pp.2028~2037 (2007)
- Haslam DW, "Obesity", Lancet, 366, pp.1197~1209 (2005)
- Ryan JG, "Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus", Gend Med, 1, pp.86~108 (2009)
- Bray GA, "Pharmacological treatment of the overweight patient", Pharmacol Rev, 59, pp.151~184 (2007)
- 김경곤, "비만의 약물 요법", 대한의사협회지, 54(4), pp.409~418 (2011), 대한의사협회
- Luque CA, "The discovery and status of sibutramine as an anti-obesity drug", Pharmacol, 440, pp.119~128 (2002)
- James WP, "Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects", Med, 363, pp.905~917 (2010)
- Bray GA, "Update on obesity pharmacotherapy", Acad Sci, 1311, pp.1~13 (2014)
- Lucas KH, "Orlistat-a novel weight loss therapy", Pharmacother, 35, pp.314~328 (2001)
- Zhi J, "Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers", Clin Pharmacol, 35, pp.1103~1108 (1995)
- Torgerson JS, "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2diabetes in obese patients", Diabetes Care, 27, pp.155~161 (2004)
- Broom I, "Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study", Clin Pract, 56, pp.494~499 (2002)
- Filippatos TD, "Orlistat-associated adverse effects and drug interactions: a critical review", Drug Saf, 31, pp.53~65 (2008)
- Shekelle PG, "Pharmacological and surgical treatment of obesity", Evid Rep Technol Assess, pp.1~6 (2004)
- Kang JG, "Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffusecontrolled release for obesity", Diabetes Obes Metab, 12, pp.876~882 (2010)
- Halford JC, "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity", Drugs, 67, pp.27~55 (2007)
- Rothman RB, "Serotonergic drugs and valvular heart disease", Expert Opin Drug Saf, 8, pp.317~329 (2009)
- Smith SR, "Multicenter, placebo-controlled trial of lorcaserin for weight management", Med, 363, pp.245~256 (2010)
- Fidler MC, "A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults:the BLOSSOM trial", J Clin Endocrinol Metab, 96, pp.3067~3077 (2011)
- O’Neil PM, "Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study", Obesity, 20, pp.1426~1436 (2012)
- Astrup A, "Topiramate: a new potential pharmacological treatment for obesity", Obes Res, 12(Suppl), pp.167~173 (2004)
- Allison DB, "Controlled-release phentermine", topiramate in severely obese adults: a randomized controlled trial (EQUIP), 2012, pp.20, 330~342
- Gadde KM, "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3trial", Lancet, 377, pp.1341~1352 (2011)
- Garvey WT, "Two-year sustained weight loss and metabolic benefits with controlled-release phentermine", topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study, 2012, pp.95, 297~308